WellPoint to cover rotarix vaccine
WellPoint announced that effective immediately it will cover the Rotarix vaccine.
WellPoint announced that effective immediately it will cover the rotavirus vaccine, Rotarix, designed to prevent a virus which causes vomiting and diarrhea in infants and children. This decision to cover Rotarix, manufactured by GlaxoSmithKline, is based on formal recommendations announced by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP). ACIP recommended that Rotarix be added to the list of recommended inoculations offered to infants. Rotarix is a liquid given in a two-dose series to infants six to 24 weeks old.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.
